One Step Synthesis of L-DOPA

  • Yeda
  • From Israel
  • Responsive
  • Patents for licensing

Summary of the technology

Current synthetic pathways of the standard Parkinson’s disease treatment, L-DOPA (levodopa), are complicated, requiring multiple steps, and depend upon the use of either hazardous starting compounds or producing toxic side products.
The present technology offers an alternative synthetic method that is greatly simplified for the production of LDOPA. Using only Tyrosine as a feedstock, the production of L-DOPA is efficient without the generation of side products, and ecologically friendly as no toxic starting materials or side products are used or produced.


Background and Unmet Need

The use of L-DOPA by itself and in combination with other drugs for treatment in Parkinson’s disease is a multibillion-dollar market, especially with a growing elderly population worldwide. Furthermore, L-DOPA has significance as a chemical precursor used to synthesize other high-value products such as Opiates (e.g., morphine) and Catecholamines (e.g., dopamine).
Chemical and biochemical methods for L-DOPA production require either toxic starting reagents or produce toxic byproducts. Moreover, chemical-based syntheses are complicated and need multiple steps, limiting overall yield due to the loss of product at each step.
Smaller-scale biochemical production involves the direct use of recombinant enzymes for the direct conversion of Tyrosine to L-DOPA. However, currently available enzymes also react with L-DOPA converting it into different side products, reducing the yield.
Therefore there is a need to synthesize L-DOPA in a non-toxic straightforward procedure without producing side products.

The Solution

Prof. Asaph Aharoni’s group discovered a new enzyme called CYP76AD6, which has a unique capacity to react with Tyrosine and exclusively produce L-DOPA in a single step1.

Technology Essence

The present technology takes advantage of a newly discovered and highly selective Cytochrome P450, CYP76AD6. Tyrosinases or other Cytochromes that synthesize L-DOPA also perform side reactions that generate undesired products, such as dopaquinone or cycloDOPA, whereas CYP76AD6 specifically hydroxylates Tyrosine in a single step to L-DOPA, without side products.
The enzyme CYP76AD6 can be expressed and is functional both within plants and yeast. Further, CYP76AD6 can be produced as a recombinant protein in E. coli to synthesize L-DOPA both inside the cell and in vitro reactions.
Subsequently, CYP76AD6 creates a “Green” chemistry alternative as the only starting material required is the natural amino acid Tyrosine, and the only byproduct is L-DOPA.

Applications and Advantages

  • One-step reaction for L-DOPA synthesis from Tyrosine
  • Non-toxic and non-hazardous synthesis
  • Flexibility in biosynthetic production - multiple possible host systems

Development Status

The team of Prof. Asaph Aharoni identified CYP76AD6 as a novel Cytochrome P450 using transcriptome analysis of the plants red beet (Beta vulgaris) and four o’clocks (Mirabilis jalapa). They further expressed it recombinantly in Nicotiana benthamiana and yeast cells to demonstrate its functionality.


Polturak G, Breitel D, Grossman N, et al. Elucidation of the first committed step in betalain biosynthesis enables the heterologous engineering of betalain pigments in plants. New Phytol. 2016;210(1):269-283. doi:10.1111/nph.13796

Intellectual property status

  • Granted Patent
  • Patent application number :USA Granted: 10,767,201

Related Keywords

  • Agriculture and Marine Resources
  • Agriculture
  • Agriculture Machinery / Technology
  • Agricultural genetic engineering applications
  • Other
  • agriculture research

About Yeda

Yeda ("Knowledge" in Hebrew) Research and Development Company Ltd. is the commercial arm of the Weizmann Institute of Science (WIS) and is the second company of its kind established in the world.

WIS is one of the world’s leading multidisciplinary basic research institutions in the natural and exact sciences. It is located in Rehovot, Israel, just south of Tel Aviv. It was initially established as the Daniel Sieff Institute in 1934, by Israel and Rebecca Sieff of London in memory of their son Daniel. In 1949, it was renamed for Dr. Chaim Weizmann, the first President of the State of Israel and Founder of the Institute.

Yeda initiates and promotes the transfer to the global marketplace of research findings and innovative technologies developed by WIS scientists. Yeda holds an exclusive agreement with WIS to market and commercialize its intellectual property and generate income to support further research and education.

Since 1959 Yeda has generated the highest income per researcher compared to any other TTO worldwide. Weizmann has generated a number of groundbreaking therapies, such as Copaxone, Rebif, Tookad, Erbitux, Vectibix, Protrazza, Humira, and recently the CAR-T cancer therapy Yescarta.

Yeda performs the following activities:

◣ Identifies and assesses research projects with commercial potential.
◣ Protects the intellectual property of WIS and its scientists.
◣ Licenses WIS' inventions and technologies to industry.
◣ Establishes new Startup companies based in WIS Intellectual Property
◣ Channels funding from industry to research projects.

Our portfolio covers a broad spectrum of the natural sciences, including:

◣ Agriculture and Plant Genetics, including Bio-fuels
◣ Chemistry and Nanotechnology
◣ Environmental Sciences and Solar Energy
◣ Mathematics and Computer Science
◣ Medical Devices
◣ Pharmaceuticals and Diagnostics
◣ Physics and Electro-Optics
◣ Research Tools


Never miss an update from Yeda

Create your free account to connect with Yeda and thousands of other innovative organizations and professionals worldwide


Send a request for information
to Yeda

About Technology Offers

Technology Offers on Innoget are directly posted
and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.


Need help requesting additional information or have questions regarding this Technology Offer?
Contact Innoget support